AlphaMark Advisors’s Invesco Pharmaceuticals ETF PJP Stock Holding History

AlphaMark Advisors’s Portfolio PJP Stock Details PJP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-14	Closed	-$1K	–	785
2023 Q4	$1K	Buy	+14	New	+$1K	﹤0.01%	690

Other funds holding PJP

PAM

Peak Asset Management Louisville, Colorado $680M AUM 22.27% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return

FGA

Fortis Group Advisors Westwood, New Jersey $626M AUM 33.6% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

AlphaMark Advisors's PJP Position: Q1 2024 in Review

AlphaMark Advisors sold out of Invesco Pharmaceuticals ETF (PJP) in Q1 2024, closing a stake of 14 shares — an estimated $1K sold.

AlphaMark Advisors first reported a position in PJP in Q4 2023 and held it in 1 quarter. The position peaked at $1K in Q4 2023. 93 funds tracked by Wall St. Rank hold PJP as of Q1 2024.

AlphaMark Advisors reported no remaining Invesco Pharmaceuticals ETF position as of Q1 2024 after selling out during the quarter.
AlphaMark Advisors sold 14 Invesco Pharmaceuticals ETF shares in Q1 2024, an estimated $1K.
AlphaMark Advisors first reported a position in Invesco Pharmaceuticals ETF in Q4 2023 and held it in 1 quarter.
AlphaMark Advisors's Invesco Pharmaceuticals ETF position peaked at $1K in Q4 2023.
93 funds tracked by Wall St. Rank held Invesco Pharmaceuticals ETF as of Q1 2024.

Based on AlphaMark Advisors's 13F filing for Q1 2024, filed 18 Apr 2024.